NervGen Pharma (NGEN)
NASDAQ:NGEN
NGEN Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NGEN Stock 12 Month Forecast
Average Price Target
$7.67
▲(83.49% Upside)
| Highest Price Target$12.00 | Average Price Target$7.67 | Lowest Price Target$5.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Maxim Group
$10→$12
Buy
187.08%
Upside
Assigned
04/08/26
Stifel Nicolaus
$6.75→$5.5
Buy
31.58%
Upside
Assigned
04/06/26
Research Capital
$5.5
Buy
31.58%
Upside
Reiterated
04/02/26
This analyst loves NervGen PharmaUddin said NervGen recently completed its end-of-Phase 2 meeting with the U.S. Food and Drug Administration, with initiation of a Phase 3 trial in chronic tetraplegia anticipated in mid-2026. He added that the company expects to report gait analysis data from its ongoing spinal cord injury study by the second quarter of 2026, including measures of joint kinematics, inter-joint coordination and postural stability across treatment groups.
Paradigm
$3.61→$7
Buy
67.52%
Upside
Reiterated
06/17/25
Raymond James
$2.51→$4.33
Buy
3.62%
Upside
Reiterated
06/11/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Maxim Group
$10→$12
Buy
187.08%
Upside
Assigned
04/08/26
Stifel Nicolaus
$6.75→$5.5
Buy
31.58%
Upside
Assigned
04/06/26
Research Capital
$5.5
Buy
31.58%
Upside
Reiterated
04/02/26
This analyst loves NervGen PharmaUddin said NervGen recently completed its end-of-Phase 2 meeting with the U.S. Food and Drug Administration, with initiation of a Phase 3 trial in chronic tetraplegia anticipated in mid-2026. He added that the company expects to report gait analysis data from its ongoing spinal cord injury study by the second quarter of 2026, including measures of joint kinematics, inter-joint coordination and postural stability across treatment groups.
Paradigm
$3.61→$7
Buy
67.52%
Upside
Reiterated
06/17/25
Raymond James
$2.51→$4.33
Buy
3.62%
Upside
Reiterated
06/11/25
Best Analysts Covering NervGen Pharma
3 Months
xxx
Success Rate
2/3 ratings generated profit
Average Return
+11.27%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +11.27% per trade.
1 Year
Success Rate
3/3 ratings generated profit
Average Return
+89.20%
reiterated a buy rating 10 months ago
Copying Michael W. Freeman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +89.20% per trade.
2 Years
xxx
Success Rate
3/3 ratings generated profit
Average Return
+56.27%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +56.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NGEN Analyst Recommendation Trends
Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
2
1
0
2
3
Buy
0
0
0
0
3
Hold
1
36
42
41
6
Sell
0
9
9
9
0
Strong Sell
0
0
0
0
0
total
3
46
51
52
12
Each month's total comprises the sum of three months' worth of ratings.
NGEN Financial Forecast
NGEN Stock Forecast FAQ
What is NGEN’s average 12-month price target, according to analysts?
Based on analyst ratings, NervGen Pharma’s 12-month average price target is 7.67.
What is NGEN’s upside potential, based on the analysts’ average price target?
NervGen Pharma has 83.49% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NGEN a Buy, Sell or Hold?
NervGen Pharma has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is NervGen Pharma’s price target?
The average price target for NervGen Pharma is 7.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $5.50. The average price target represents 83.49% Increase from the current price of $4.18.
The highest analyst price target is $12.00 ,the lowest forecast is $5.50. The average price target represents 83.49% Increase from the current price of $4.18.
What do analysts say about NervGen Pharma?
NervGen Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of NGEN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.